Angiodroid is an Italian company specialising in medical technologies for vascular surgery, interventional radiology, interventional cardiology and interventional angiology. It stands out for its patented and certified (CE marked) automatic carbon dioxide (CO₂) injection system for angiography examinations. This solution, which is particularly suitable for patients at high risk of contrast-induced nephropathy, offers a non-nephrotoxic alternative to gadolinium or iodine. The Angiodroid injector features precise control of injection volume and pressure, a touchscreen interface combined with a wireless remote control, and a safety system incorporating a one-way valve and automatic catheter flushing, ensuring the safety and quality of radiological images. In February 2023, Angiodroid became a public limited company (SpA) following a major €7 million fundraising round, strengthening its international presence and the development of its products, particularly Angiopulse.